Thailand has been hailed by The Global Fund as the golden example of a well-planned and well-managed transition. When Thailand submitted its TB/HIV concept note in June 2014, the country announced that this would be the last time it requested money from The Global Fund. The country indicated that it would transition in just two years, shorter than the standard three-year Global Fund grant cycle. This is an unusual situation.
Access to essential medicines remains a challenge in most developing countries and is among the Millennium Development Goal targets. Over the past decade, international organizations including the Global Fund, the World Bank, USAID have invested in improving access to essential medicines.
The Global Fund is participating in an initiative to leverage private sector funding to speed up delivery of, and expand access to, health products such as contraceptives, bed nets and medicines. The initiative is called the “Pledge Guarantee for Health.”
Procurement costs for HIV, TB and malaria commodities have either come down or remained stable over the past seven years, according to an analysis conducted by Frank Wafula, Ambrose Agweyu and Kate Macintyre at Aidspan. The findings of the analysis are described in a working paper published on April 29, 2013 on the Aidspan website.
The Global Fund has developed new minimum standards for implementers. Entities covered by the standards include principal recipients (PRs), large sub-recipients (SRs) and other associated actors, such as public- or private-sector entities involved in the pharmaceutical and health products procurement and supply chain, as well as components of the national health system.
The Global Fund is encouraging Myanmar to ask for some new money in its request for continued funding for its two HIV grants, in order to permit a faster scale-up of antiretroviral treatment (ART). The encouragement came following a visit to Myanmar by General Manager Gabriel Jaramillo in August 2012.
A report published recently in a medical journal has focussed renewed attention on the problem of donated malaria drugs being stolen and then sold in the private sector in Africa. According to researchers, in a study conducted between 2007 and early 2010, of nearly 900 samples purchased from private pharmacies in 11 African cities, 6.5% were stolen.
In Issue 111, GFO reported briefly on a Global Fund Board decision in November 2009 to further modify its Quality Assurance Policy for Pharmaceutical Products. This article provides some background information and further details of the decision.
The Board had previously approved a revised Quality Assurance Policy at its meeting in November 2008. That revised policy came into effect on 1 July 2009.
Global Fund Board Approves Proposals for Phase 1 of the "AffordableMedicines Facility - Malaria" (AMFm) Funding Stream
At its recent meeting in Addis Ababa, the Global Fund Board approved 10 proposals under Phase 1 of a small innovative new funding programme called the "Affordable Medicines Facility - Malaria" (AMFm), which is designed to provide support for interventions promoting and facilitating the use of artemisinin combination therapies (ACT).
[The following Q&A regarding the pricing agreement was released on 6 April 2004 by the same four organizations as the above press release.]